---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-087301"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:46:21.604582+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Milestone Q2 net loss $9.4M; FDA acceptance of CARDAMYST NDA with PDUFA March 2025

## Summary
- FDA accepted CARDAMYST (etripamil) NDA for PSVT; PDUFA target date set for March 2025.
- Cash and equivalents $83.3M as of June 30, 2024, expected to fund operations into 2026.
- Q2 2024 net loss $9.4M vs $16.0M in Q2 2023; R&D expenses down to $2.8M from $8.6M.
- Stuart Duty and Andrew Saik appointed as independent directors to the board.
- Phase 3 AFib-RVR trial design ongoing; enrollment planned for first half of 2025.

## SEC filing metadata
- accession: 0001104659-24-087301
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465924087301/0001104659-24-087301-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465924087301/tm2421158d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-087301
- JSON: https://secwatch.observer/filing/0001104659-24-087301.json
- Plain text: https://secwatch.observer/filing/0001104659-24-087301.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.